Evidence map›Paper›PMID 32523660›Full record

ArticleTherapeutic advances in hematology2020

Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd).

Ja Min Byun, Sung-Soo Yoon, Youngil Koh, Chang-Ki Min, Jae Hoon Lee, Jaemin Jo, Hyunkyung Park, Jiyun Lee, Ka-Won Kang, Yoojin Lee and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Ja Min ByunDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0003-1780-5553
Sung-Soo YoonDepartment of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongro-gu, Seoul 03080, Republic of Korea.
Youngil KohDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.
Chang-Ki MinDepartment of Internal Medicine, Seoul St. Mary's Hospital, Seoul, Korea.
Jae Hoon LeeDepartment of Internal Medicine, Gachon University Gil Hospital, Incheon, Korea.
Jaemin JoDepartment of Internal Medicine, Jeju National University Hospital, Jeju, Korea.
Hyunkyung ParkDepartment of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea.
Jiyun LeeDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Ka-Won KangDepartment of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Yoojin LeeDepartment of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
and the Korean Multiple Myeloma Working Party (KMMWP)
Seoul National University · KRSeoul National University Bundang Hospital · KRJeju National University Hospital · KRKorea University · KRThe Catholic University of Korea Seoul St. Mary's Hospital · KRUlsan College · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTraditionally believed to be an integral part of multiple myeloma (MM) treatment, the role of hematopoietic stem-cell transplantation (HSCT) is being challenged. As such, we sought to evaluate the impact of HSCT in the era of novel agents.

methodsA multicenter, retrospective, longitudinal cohort study was carried out between January 2016 and December 2018. A total of 55 patients who received VTD (bortezomib-thalidomide-dexamethasone) as first-line treatment and KRd (carfilzomib-lenalidomide-dexamethasone) as second-line treatment were analyzed for outcomes.

resultsThe enrolled patients were divided into Group 1, defined as those who continued KRd treatment until progression (

conclusionsIn conclusion, even with the advent of novel agents, HSCT still remains a valuable treatment modality with additive efficacy.

Indexed as

hematopoietic stem-cell transplantationmultiple myelomanovel therapy

Identifiers

PMID32523660
PMCPMC7236395
OpenAlexW3025849874

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.